At a glance
ClinicalIndex Comparison RecordPhase 2Completed
Drug / intervention
lovastatindrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Cholesterol Reduction in Seniors Program (CRISP)
National Heart, Lung, and Blood Institute (NHLBI)·interventional·Posted Oct 28, 1999·Updated Feb 18, 2016
In Brief
A Phase 2 clinical trial evaluating lovastatin for Atherosclerosis and 5 related conditions. Completed.
Detailed Summary
To conduct a pilot study to determine whether lowering elevated serum cholesterol levels with 3-hydroxy-3-methyl-glutaryl coenzyme A (HMG CoA) reductase inhibitors reduced mortality due to the sequelae of atherosclerotic cardiovascular disease in older men and women.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAtherosclerosis, Cardiovascular Diseases, Coronary Disease, Heart Diseases, Hypercholesterolemia, Myocardial Ischemia
Countries--
Collaborators--
Timeline
Phase 2CompletedFinished
19901991199219931994199519961997199819992000200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartJul 1990
Study CompletionJun 1992
First PostedOct 1999
TodayJul 2026
First PostedOct 28, 1999
Enrollment StartJul 1, 1990
Study CompletionJun 1, 1992
TodayJul 2, 2026
Posted 26.7 years ago
Interventions
lovastatindrug